Tian Zhang, Director of Clinical Research at UT Southwestern Medical Center, spotlights key Prostate Cancer updates from ESMO25.
“Thorough, insightful review of PARP inhibitors in prostate cancer from Neeraj Agarwal – monotherapy & rationale for combos. Important to test our patients for HRR alterations!”
“Karim Fizazi with primary analysis of CAPITELLO 281, capivasertib with ADT in metastatic hormone sensitive prostate cancer improved rPFS for PTEN deficient disease. >6000 patients screened (!!) Concurrent pub Annals Oncology.”
“Great talk from Paul Nguyen – enzalutamide did not improve MFS for high risk localized prostate cancer in ENZARAD.”
“Always enjoy Arun Azad discussions — brings forward critical issues — may not get to OS due to crossover (better for patients), optimal dosing and early hold, & late term toxicities. The Peter Mac Cancer Centre group has this down.”
“Rahul Aggarwal showing MFS & time to castration resistance benefit of ADT and apalutamide in the ALLIANCE PRESTO trial — important work for PSA recurrent disease.”
You can also read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
ESMO 2025 Day 3 Highlights Not to Miss
